Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Slides:



Advertisements
Similar presentations
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Advertisements

ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Prevalence (%) estimates of diabetes (20-79 years) 2010.
ACCORD Design and Baseline Characteristics
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM
Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.
Diabetic Dyslipidemia in Practice
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
Diabetes and Risk of CV Outcomes
Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.
New Insights on PPAR Agonists For Cardiovascular Disease
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Cholesteryl Ester Transfer Protein Inhibitors
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
Select Topics in Cardiovascular Medicine
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.
Impacting CV Risk With Diabetes Medications
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Impacting CV Risk With Diabetes Medications
T2DM and CV Outcomes Trials: A Deep Dive!
Diabetes Increases Risk of CVD
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Evaluating LDL-C Recommendations
Statins and Glucose Metabolism: Are All Agents Alike?
UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes
Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.
Growing Diabetes Pandemic Worldwide
Tackling CV Risk in T2DM.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM
EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Diabetes and Cardiovascular Disease Risk: The Hard Truth
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Learning Objectives Metabolic Abnormalities Associated With T2D.
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Antihyperglycemic Therapy
Diabetes and Cardiovascular Disease Risk: The Hard Truth
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pharmacotherapy for Diabetic Coronary Disease:
How to Optimize Cholesterol Management in High-Risk CV Patients
Elevated Admission Plasma Glucose Following ACS
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
2015 EASD In Review: CV Risk management in t2dm
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Presentation transcript:

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Diabetes in Cardiology Cohorts

High Residual Risk of Diabetes: Observations from the Statin Trials

Mortality Impact of Glycemic Control: UGDP

Blood Glucose and Vascular Risk in Diabetes: UKPDS Findings

UKPDS Metformin Sub-Study: CHD Events

Off Target Adverse Drug Effects

ADOPT: Cardiovascular events

Summary of RCT & Meta-Analysis Data on TZDs and MI Risk

CV Effects of More Intensive Glucose Control in Recent Large-Scale Trials

2009 ADA/AHA/ACC Statement Recommendations

Cautions for Diabetes Medications in CHD Patients: Beware the Product Label

Proposed Algorithm for Glucose Treatment in T2DM Patients With/At risk for CVD

Proposed Algorithm for Glucose Treatment in T2DM Patients With/At risk for CVD

2012 Guidance from ADA/EASD for Glucose Management

ORIGIN Key Results

Converging Pressures for Regulatory Change: Beyond A1C

Summary of Revised Guidance for Diabetes Drug Development

New FDA Regulatory Guidance for Drugs for Type 2 Diabetes

Present Landscape of CVD Outcomes Trials in Type 2 DM

SAVOR-TIMI 53 Summary

SAVOR-TIMI 53 Summary

EXAMINE

EXAMINE

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)